dr. moore on benefit of mirvetuximab soravtansine in patients with ovarian cancer
Published 4 years ago • 361 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
2:28
dr. moore on the role of mirvetuximab soravtansine in ovarian cancer
-
1:49
dr. moore on safety profile of mirvetuximab soravtansine in ovarian cancer
-
2:15
dr. moore on early-phase data with mirvetuximab soravtansine in ovarian cancer
-
2:19
dr. moore on anticipated impact of the mirasol trial in platinum-resistant ovarian cancer
-
2:43
dr. moore on the impact of solo-1 in ovarian cancer
-
2:23
dr. moore on unanswered questions with parp inhibitors in ovarian cancer
-
1:16
dr. moore discusses combinations in ovarian cancer
-
1:15
dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
-
2:20
dr. moore on the results of the nova trial in ovarian cancer
-
1:13
dr. o’malley on the activity of mirvetuximab soravtansine in ovarian cancer
-
2:03
dr. moore on treatment for patients with ovarian cancer who develop resistance to parp inhibitors
-
1:50
an overview of a study exploring mirvetuximab soravtansine in ovarian cancer
-
1:40
dr. moore on immunotherapy and parp combinations in brca-mutated ovarian cancer
-
2:09
dr. moore on the nova trial for ovarian cancer
-
1:34
dr. moore on challenges with immunotherapy in ovarian cancer
-
0:59
dr secord on mirvetuximab soravtansine in platinum-sensitive, frα-high ovarian cancer
-
1:47
mirvetuximab soravtansine remains well tolerated in platinum-resistant ovarian cancer
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
0:54
dr. moore on the prevalence of ovarian cancer